Dartmouth-Hitchcock Helps Open New COVID-19 Clinical Trials in Six Days

Dartmouth-Hitchcock Health just helped open two Phase III COVID-19–related therapeutic studies in six business days. The Gilead-sponsored studies, one of patients with moderate COVID-19 and the other with patients suffering more serious symptoms, are evaluating the safety and antiviral activity of Remdesivir (GS-5734™) against the condition.